ARCHIVES

Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

ODAC Reviews Post-Marketing Studies for Eight Indications

March 21, 2003

Also in this 8-page issue: Use cancer mortality, not 5-year survival, to track progress against cancer, researchers say.

July 29, 2005

NCI Advisory Group, Other Cancer Meetings

August 30, 1991

Barbara Rimer Named NCAB Chairman; First Women Appointed To Lead Board

September 16, 1994

Congress Urges CMS To Soften Proposal For Coverage Of ESAs in Oncology.

July 20, 2007

1985 International Cancer Congress to Be In Budapest

September 24, 1982